What do systematic reviews say?

Fluoxetine vs tricyclic antidepressants (TCAs)

Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with TCAs (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.97 [0.77, 1.22]
  24 studies · 2124 participants
  Moderate

Fluoxetine vs ABT‐200

Fluoxetine may leads to lower failure to complete ‐ side effects ‐ compared with ABT‐200 (low certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.08 [0.02, 0.27]
  1 study · 144 participants
  Low

Fluoxetine vs phenelzine

It is very uncertain whether fluoxetine changes failure to complete ‐ side effects ‐ compared with phenelzine (very low certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.32 [0.01, 8.26]
  1 study · 40 participants
  Very low

Fluoxetine vs pramipexole

Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with pramipexole (low certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.55 [0.24, 1.26]
  1 study · 105 participants
  Low

Fluoxetine vs pramipexole

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Fluoxetine vs pramipexole

Fluoxetine may leads to lower failure to complete ‐ total ‐ compared with pramipexole (low certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.12 [0.03, 0.42]
  1 study · 105 participants
  Low

Fluoxetine vs pramipexole

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with pramipexole (low certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.49 [0.05, 4.51]
  1 study · 105 participants
  Low

Fluoxetine vs pramipexole

Fluoxetine may leads to lower failure to complete ‐ side effects ‐ compared with pramipexole (low certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.06 [0.01, 0.5]
  1 study · 105 participants
  Low

Fluoxetine vs reboxetine

Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with reboxetine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.77 [0.55, 1.1]
  3 studies · 721 participants
  Moderate

Fluoxetine vs reboxetine

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 205 participants
  Moderate

Fluoxetine vs reboxetine

Fluoxetine probably leads to lower failure to complete ‐ total ‐ compared with reboxetine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.6 [0.44, 0.82]
  4 studies · 764 participants
  Moderate

Fluoxetine vs reboxetine

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with reboxetine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.92 [0.47, 1.77]
  3 studies · 464 participants
  Moderate

Fluoxetine vs agomelatine

Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with agomelatine (low certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.44 [0.99, 2.09]
  1 study · 515 participants
  Low

Fluoxetine vs reboxetine

Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with reboxetine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.41 [0.15, 1.09]
  2 studies · 211 participants
  Moderate

Fluoxetine vs sertraline

Fluoxetine probably leads to higher failure to respond (reduction ≥ 50% on HDRS) compared with sertraline (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.37 [1.08, 1.74]
  6 studies · 1188 participants
  Moderate

Fluoxetine vs sertraline

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 1160 participants
  Moderate

Fluoxetine vs sertraline

Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with sertraline (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.17 [0.93, 1.49]
  9 studies · 1591 participants
  Moderate

Fluoxetine vs sertraline

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with sertraline (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.09 [0.68, 1.77]
  5 studies · 1056 participants
  Moderate

Fluoxetine vs sertraline

Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with sertraline (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.25 [0.92, 1.7]
  9 studies · 1591 participants
  Moderate

Fluoxetine vs tianeptine

Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with tianeptine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.12 [0.75, 1.67]
  3 studies · 387 participants
  Moderate